Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease

BACKGROUND: There are little data on positioning biologics in Crohn's disease (CD). AIMS: We aimed to assess the comparative effectiveness and safety of ustekinumab vs tumour necrosis factor-alpha (anti-TNF) agents after first-line treatment with anti-TNF in CD. METHODS: We used Swedish nationw...

Descripción completa

Detalles Bibliográficos
Autores principales: Eriksson, Carl, Söderling, Jonas, Karlqvist, Sara, Bröms, Gabriella, Everhov, Åsa H., Bergemalm, Daniel, Ludvigsson, Jonas F., Olén, Ola, Halfvarson, Jonas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293383/
https://www.ncbi.nlm.nih.gov/pubmed/36929241
http://dx.doi.org/10.1007/s10620-023-07897-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293383/
https://www.ncbi.nlm.nih.gov/pubmed/36929241
http://dx.doi.org/10.1007/s10620-023-07897-2

Ejemplares similares